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Background. Bacterium and leucocyte counts in urine can be measured by urine ﬂow cytometry (UFC). They are used to predict
signiﬁcant bacterial growth in urine culture and to diagnose infections of the urinary tract. However, little information is
available on appropriate UFC cut-oﬀ values for bacterium and leucocyte counts in speciﬁc clinical presentations. Objective. To
develop, validate, and evaluate adapted cut-oﬀ values that result in a high negative predictive value for signiﬁcant bacterial
growth in urine culture in common clinical presentation subgroups. Methods. This is a single center, retrospective, observational
study with data from patients of the emergency department of Bern University Hospital, Switzerland, with suspected infections
of the urinary tract. The patients presented with diﬀerent symptoms, and urine culture and urine ﬂow cytometry were
performed. For diﬀerent clinical presentations, the patients were grouped by (i) age (>65 years), (ii) sex, (iii) clinical symptoms
(e.g., fever or dysuria), and (iv) comorbidities such as diabetes and immunosuppression. For each group, cut-oﬀ values were
developed, validated, and analyzed using diﬀerent strategies, i.e., linear discriminant analysis (LDA) and Youden’s index, and
were compared with known cut-oﬀs and cut-oﬀs optimized for sensitivity. Results. 613 patients were included in the study.
Signiﬁcant bacterial growth in urine culture depended on clinical presentation and ranged from 32.3% in male patients to 61.5%
in patients with urinary frequency. In all clinical presentations, the predictive accuracy of UFC leucocyte and UFC bacterium
counts was good for signiﬁcant bacterial growth in urine culture (AUC ≥ 0 88). The adapted LDA95 equations did not exhibit
consistently high sensitivity. However, the in-house cut-oﬀs (test positive if UFC leucocytes > 17/μL or UFC bacteria > 125/μL)
were highly sensitive (>90%). In female, younger, and dysuric patients, even higher cut-oﬀs for UFC leucocytes (169/μL, 169/μL,
and 205/μL) exhibited high sensitivity. Speciﬁcity was insuﬃcient (<0.9) for all tested cut-oﬀs. Conclusions. For various clinical
presentations, signiﬁcant bacterial growth in urine culture can be excluded if ﬂow cytometry measurements give a bacterial
count of ≤125/μL or a leucocyte count of ≤17/μL. In female patients, dysuric patients, and patients younger than ≤65 years, the
leucocyte cut-oﬀ can be increased to 170/μL.
1. Introduction
The prevalence and severity of urinary tract infections
(UTI) depends on demographic characteristics, the clinical
presentation, and the individual medical history [1, 2].
For instance, UTI is the second most prevalent infection
seen in women aged 65 years or over [3], with a gradual
increase with age [4]. In susceptible subgroups, such as
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immunosuppressed, diabetic, and geriatric patients, there is a
greater risk of death and life-threatening complications such
as urosepsis [3, 5, 6]. In diabetic patients, the mortality attrib-
uted to an infection is higher than that in the population
without diabetes [7]. Thus, susceptible subgroups require
special attention with respect to UTI.
The gold standard for the diagnosis of a UTI is still
signiﬁcant bacterial growth in urine culture combined with
the clinical presentation of the patient [8]. However, the
results of a urine culture can take up to several days—usually
at least 24 hours—before they become available, and a
prompt decision on treatment has to be taken within a
shorter time frame. Thus, the decision for empirical antibi-
otic treatment is often based on clinical symptoms and more
rapidly available laboratory tests, such as urine dipstick,
microscopic examination, and, nowadays, urine ﬂow cytom-
etry [9]. All of these are considered useful tools for predict-
ing signiﬁcant bacterial growth in urine culture and are
therefore used to diagnose a UTI.
Urine ﬂow cytometry (UFC) has the advantage that it is
standardized, less expensive than urine culture and micro-
scopic examination, and rapidly available—especially in
comparison to urine culture [10].
To rule out negative urine culture (nonsigniﬁcant bacterial
growth), most studies have focused on ﬁxed cut-oﬀs deter-
mined by UFC for counts of leucocytes and bacteria in the
urine (UFC leucocytes and UFC bacteria, respectively) that
help to decide whether culturing is rational and indicated
for treatment [11–13]. Several diagnostic algorithms suggest
an “optimal” cut-oﬀ for predicting signiﬁcant bacterial
growth in urine culture [14]. Thus, the diagnosis of a UTI
remains challenging, as the individual medical history and
comorbidities of the patient might inﬂuence the diagnostic
validity of ﬁxed UFC cut-oﬀs for predicting signiﬁcant bacte-
rial growth in urine culture. Only a few studies have evaluated
the use of adjusted cut-oﬀs for bacterium and leucocyte
counts determined by UFC in speciﬁc clinical presenta-
tions—such as greater age, sex, and typical symptoms such
as dysuria, renal insuﬃciency, diabetes, and other immuno-
suppression [1, 15–17].
The aim of this study is thus to develop, validate, and eval-
uate adapted cut-oﬀ values that result in a high negative predic-
tive value for signiﬁcant bacterial growth in urine culture in
common and important clinical presentation subgroups—such
as women, dysuric patients, diabetics, immunosuppressed
patients, or patients younger than 65 years of age.
2. Methods
2.1. Study Design. This is a single-center, retrospective, obser-
vational study with data from patients of the emergency
department (ED) of Bern University Hospital, Switzerland.
More than 35,000 patients per year are treated at our ED.
The patients’ data were anonymized. The study was
approved by the ethical committee of the canton of Berne
(KEK: 2016-01298) and performed according to Swiss law.
Individual informed consent was waived, as the data had
been anonymized.
2.2. Study Population, Deﬁnition of Patient Clinical
Presentation, and Data Extraction.This is a secondary analysis
of a published data set, in which we developed generic tools to
predict signiﬁcant bacterial growth in urine culture from UFC
measurements [14]. In the study presented here, we focus on
patient characteristics: (i) age (>65 years and ≤65 years); (ii)
gender; (iii) fever (>38.0°C on presentation in accordance with
a previous UFC study [15]); (iv) urinary symptoms such as
dysuria, urinary frequency, and UTI-speciﬁc abdominal pain,
including suprapubic pain, lower abdominal pain, or ﬂank
pain; (v) renal insuﬃciency (classiﬁed by the medical history);
(vi) diabetic patients; and (vii) immunosuppressed patients.
Immunosuppression was deﬁned as cancer under chemother-
apy, transplantation, or a current hematological or rheumato-
logical disease.
The study population was obtained through a keyword
search for “urine culture” in the medical ﬁle. The inclusion
criteria were as follows: age> 16 years, presentation at the
ED from January 7th, 2016, to July 31st, 2016, and urine
culture and urine ﬂow cytometry obtained within 24 hours
of presentation. Thus, we included all patients for whom
the attending physician decided to carry out urine ﬂow
cytometry and urine culture, as they were assumed to have
suspected UTI. The ﬂow chart and reasons for exclusion
are shown in Figure 1. The medical history and clinical pre-
sentation are routinely recorded by the attending physician.
The records were stored in our emergency department’s
medical database (E-Care, ED 2.1.3.0, Turnhout, Belgium).
2.3. Laboratory Analysis. Urine culture (gold standard) was
obtained from a clean midstream/catheter urine at the ED
and sent to the laboratory within two hours. After 24 h and
48 h of incubation, the results of the urine culture were
recorded by the Department of Clinical Microbiology. Urine
ﬂow cytometry was performed by the Center of Laboratory
Medicine at Bern University Hospital (the Inselspital), an
ISO 17025-accredited laboratory. The UFC was performed
with the UX-2000 ﬂow cytometer (Sysmex Corporation,
Kobe, Japan). The UFC is fully automated, and results
can be viewed online by the attending physician 30min
after the start of the analysis. The procedures for urine
collection, storage, and analysis are described in a previous
publication [14].
2.4. Outcomes. Signiﬁcant bacterial growth in the urine
culture, deﬁned as at least 104 colony forming units (CFU)
per mL, was taken as the gold standard.
2.5. Statistics. Statistical analysis was performed with Stata®
13.1 (StataCorp, College Station, Texas, USA).
To validate the obtained cut-oﬀs, the data set was ran-
domly divided into training and validation sets in a 1 : 1 ratio.
The diﬀerent clinical presentations were separately ana-
lyzed as follows: First, the area (AUC) under a receiver
operating curve (ROC) and its 95% conﬁdence interval
(CI) were calculated following logistic regression. This was
then used to determine the discriminatory performance of
UFC bacterium and UFC leucocyte counts for predicting
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signiﬁcant bacterial growth in urine culture in the speciﬁc
clinical presentation.
Second, the following adjusted cut-oﬀs for bacterium and
leucocyte counts in UFC were established for the training set:
(i) Cut-oﬀs with the highest Youden’s index
(sensitivity + specificity − 1)
(ii) Sensitivity-optimized LDA95 equations (test positive
⇔ ln UFC leucocytes + 1 > a × ln UFCbacteria +
1 – b); the parameters a and b are determined
through discriminant analysis and the optimization
criterion that sensitivity should be above 0.95 in
the training set (for easier reading and to derive a
formula valid for all UFC values, the formula
presented by Monsen and Ryden was slightly
changed [18])
(iii) Optimized sensitivity cut-oﬀs deﬁned as the highest
bacterium or leucocyte count with a sensitivity ≥
0 95; a test was deﬁned as negative if both cut-oﬀs
are below the identiﬁed thresholds.
Third, these cut-oﬀs were used in the validation
sample to assess the diagnostic performance with respect
to sensitivity, speciﬁcity, and positive and negative likeli-
hood ratio (LR). The in-house cut-oﬀ for a positive test
used at our hospital is UFC bacteria > 125/μL or UFC
leucocytes > 17/μL; this was also validated. Last, the diag-
nostic performance of the diﬀerent cut-oﬀs in the clinical
presentations was compared among the diﬀerent methods.
3. Results
In total, 613 (100%) patients with a median age of 60
years (interquartile range: 46-75) were included in the
analysis (Figure 1).
Table 1 shows that more than half of the study popula-
tion was aged <65 years old (55.6%). Immunosuppression
was found in 35.1%. Fever was present in 31.4%, while dia-
betes was coded in 22.2% and renal insuﬃciency in 33.9%
of the patients. Typical symptoms for a UTI were less common,
with 18.3% dysuria, 12.7% urinary frequency, and 19.4% with
UTI-speciﬁc abdominal pain (including lower abdominal pain,
suprapubic pain, and ﬂank pain). Three hundred seven (307)
consultations were randomized to the training set and 306
patients to the validation set. Signiﬁcant bacterial growth in
urine culture, deﬁned as at least 104CFU/mL, was found in
approximately four out of ten patients (40.2%). E. coli was
identiﬁed in 48.6% of those patients.
The most common urological diagnosis was possible
urogenital infection (29.5%). Other important discharge
diagnoses were uncomplicated UTI (13.4%) and urosepsis
(9.6%), as well as “no speciﬁc urological diagnosis” (25.6%,
e.g., other infectious disease and respiratory problem).
3.1. Incidence of Signiﬁcant Bacterial Growth in Urine Culture
and Predictive Accuracy of UFC Bacterium and UFC
Leucocyte Counts. The incidence of signiﬁcant bacterial
growth in urine culture was higher in females and older
people (49.2% and 46.3%, respectively) than in males and
younger people (32.3% and 35.8%, respectively). Depending
on the clinical symptoms and comorbidities, the incidence
ranged from 32.3% in male patients to 61.5% in patients with
urinary frequency (Table 2). The incidence of signiﬁcant
bacterial growth in the urine culture in the diﬀerent clinical
presentations did not diﬀer signiﬁcantly between the training
and validation sets (all p > 0 05).
The discriminatory accuracy values of UFC leucocyte and
UFC bacterium counts to predict signiﬁcant bacterial growth
in urine culture measured by the AUC were at least 0.88 in all
studied clinical presentations. In female patients, the AUC
was 0.88 (95% CI: 0.85, 0.92) and in male patients 0.95
(95% CI: 0.92, 0.97). In the other clinical presentations, the
95% CI of the AUC overlapped, although the actual AUC
values were slightly diﬀerent (Table 2).
Exclusion (n = 280):
(i) Urine ﬂow cytometry missing (n = 121)
(ii) Urine culture missing (n = 159)
Patients identiﬁed through the keyword search “urine culture” with diﬀerent
semantic combinations/abbreviations in all medical reports from
7th January 2016–31st July 2016
(n = 893)
Patients included in the analysis
(n = 613) 
Randomized split into training set (50%) and validation set (50%):
(i) Training set (n = 307)
(ii) Validation set (n = 306)
Figure 1: Flowchart.
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3.2. Adapted Cut-Oﬀs with the Highest Youden’s Index. The
training sample was used to ﬁnd adapted cut-oﬀs for
UFC bacterium and UFC leucocyte counts that maximized
Youden’s index in each clinical subgroup. Striking diﬀer-
ences in the cut-oﬀs were found (Table 3). For example,
if Youden’s cut-oﬀ was 74/μL for UFC leucocyte counts
and 63/μL for UFC bacterium counts, Youden’s index in
patients with renal insuﬃciency was 0.5. In patients with-
out diagnosed renal insuﬃciency, the Youden-based cut-oﬀ
for UFC leucocyte counts was 108/μL and for UFC bacterium
counts 470/μL, giving Youden’s index of 0.7.
Maximal values of Youden’s index were associated with
high-sensitivity values, which were all above 88.2%, with
lower sensitivity (<90%) in diabetic and female patients in
the validation set. Speciﬁcity was lower, with a maximum
of 88.3% (range: 46.2% in patients with UTI-speciﬁc
abdominal complaints up to 88.3% in febrile patients).
The high-sensitivity values were reﬂected by a small nega-
tive likelihood ratio (<0.1), indicating a large decrease in
the posttest probability of signiﬁcant bacterial growth, while
the positive likelihood ratio was <5 in all clinical presenta-
tions (slight increase in posttest probability) [19].
3.3. Adapted Cut-Oﬀs with Optimized Sensitivity > 95%
Compared with the In-House Cut-Oﬀs. Two diﬀerent
methods were used to adapt cut-oﬀs to high sensitivity. The
ﬁrst approach was to use the adapted LDA95 equation. The
second approach was to optimize sensitivity (>95%) for each
group of patients—ﬁrstly for the UFC bacterium count and
secondly for the UFC leucocyte count—and then to combine
these cut-oﬀs in a single test. A test was deﬁned as positive if
either the UFC leucocyte or the UFC bacterium cut-oﬀ was
exceeded. These two approaches gave diﬀerent results for
diagnostic performance (Tables 4 and 5). When speciﬁcity
was moderate, the adapted LDA95 equations failed to show
good sensitivity (>90%) for several groups of patients,
including male, older, and diabetic patients (Table 4).
For all clinical presentations, the in-house cut-oﬀs (test
positive if UFC leucocytes > 17/μL or UFC bacteria > 125
/μL) exhibited high sensitivity and good negative likelihood
ratios (<0.1). In total, 184 of the 613 patients (30.0%) had
UFC leucocyte < 17/μL and UFC bacteria < 125/μL in the
ﬂow cytometry results. The adapted sensitivity cut-oﬀ
values were similar to the in-house values. In female, youn-
ger, and dysuric patients, high sensitivity was obtained even
with higher cut-oﬀs for UFC leucocyte counts (169/μL,
169/μL, and 205/μL) and a similar value for UFC bacterium
counts (103/μL). Speciﬁcity was low for all tested
cut-oﬀs—especially the in-house cut-oﬀ—and ranged from
22.2% in patients with urinary frequency to 60.6% in male
patients (Table 5).
4. Discussion
This is the ﬁrst study to focus on the development, evalua-
tion, and validation of cut-oﬀ parameters for UFC bacterium
and UFC leucocyte counts in diﬀerent clinical scenarios in
an emergency department population. This can then be used
to predict signiﬁcant bacterial growth in urine culture, which
in turn indicates a UTI and thus the necessity of antibiotic
treatment. The study covered patients of diﬀerent sex, age,
symptoms (UTI-speciﬁc abdominal pain, fever, urinary fre-
quency, and dysuria), and comorbidities (diabetes, renal
insuﬃciency, and immunosuppression).
In all studied clinical presentations, the discriminative
accuracy of UFC leucocyte and UFC bacterium counts for
Table 1: Patient characteristics (n = 613).
Characteristics (n (%)) Total (n = 613) Training set
(n = 307)
Validation set
(n = 306)
Sex
Male 316 (51.5) 157 (51.1) 159 (52.0)
Female 297 (48.5) 150 (48.9) 147 (48.0)
Age
>65 years 272 (44.4) 130 (42.4) 142 (46.4)
≤65 years 341 (55.6) 177 (57.6) 164 (53.6)
Clinical presentation
Dysuria 112 (18.3) 56 (18.2) 56 (18.3)
Urinary frequency 78 (12.7) 40 (13.0) 38 (12.4)
Fever (>38.0°C)1 192 (31.4) 96 (31.4) 96 (31.5)
Urinary tract infection-speciﬁc abdominal pain2 119 (19.4) 61 (19.9) 58 (19.0)
Comorbidities
Diabetes mellitus 136 (22.2) 62 (20.2) 74 (24.2)
Renal insuﬃciency 208 (33.9) 112 (36.5) 96 (31.4)
Immunosuppression 215 (35.1) 105 (34.2) 110 (36.0)
Hospitalisation 451 (73.6) 225 (73.3) 226 (73.9)
1Two values (one from the training and one from the validation set) were missing; thus, n = 611. 2This includes lower abdominal, suprapubic, and ﬂank pain.
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signiﬁcant bacterial growth in urine culture was good
(AUC ≥ 0 88). With the in-house cut-oﬀs, a test was deﬁned
as positive if UFC leucocyte counts were >17/μL or UFC
bacterium counts > 125/μL and with this exhibited high
sensitivity in all groups of patients. Compared with the
cut-oﬀs for optimized sensitivity of >95% in female, youn-
ger, and dysuric patients, high sensitivity and even higher
speciﬁcity were obtained with higher cut-oﬀs for UFC
leucocyte counts (169/μL, 169/μL, and 205/μL).
Although this is sometimes neglected in clinical prac-
tice, the posttest probability of a disease depends on the
incidence of a disease in the speciﬁc clinical setting and
the likelihood ratio (LR) of the test [20]. Given a speciﬁc
clinical presentation with a speciﬁc symptom A, the pretest
probability, the incidence of the disease, can be converted
to the odds for the disease. The odds multiplied by the
LRA(+) of the disease in the speciﬁc presentation with
symptom A and the general LRTest(+) leads to the posttest
odds, which can be transformed to the posttest probability
[19]. Posttest probability is of great help in the in-depth
interpretation of test results [21]. However, this construct
is not of great use in clinical practice, as it requires the
speciﬁc LR(+) for each symptom as well as for symptom
combinations and demands complex calculations [19].
Nevertheless, it is important that clinicians understand the
primary concept of the pre- and the posttest probability.
An alternative and more useful concept is the use of
adapted cut-oﬀs for diagnostic tests, which are, for instance,
used in the diagnosis of venous embolism with age-adjusted
D-dimers [22]. To rule out a diagnosis, it is necessary that
the adapted cut-oﬀs consider the possible higher or lower
incidence of the disease in speciﬁc subgroups; otherwise,
the test may not be valid in the speciﬁc presentation.
In our study, the incidence of signiﬁcant bacterial growth
in urine culture ranged from 32.8% in febrile patients to
61.5% in patients with urinary frequency (Table 2). These
Table 2: Discriminatory accuracy of UFC leucocyte and UFC bacterium counts measured by the area under the receiver operating curve of
the logistic regression to predict signiﬁcant bacterial growth in urine culture.
Total (n = 613) SBU (%) AUC (95% CI) Training set (n = 307) SBU (%) Validation set (n = 306) SBU (%)
Sex
Male 32.3 0.95 (0.92, 0.97) 29.9 34.6
Female 49.2 0.88 (0.85, 0.92) 48.7 49.7
Age
>65 years 46.3 0.95 (0.92, 0.97) 45.4 47.2
≤65 years 35.8 0.90 (0.86, 0.93) 34.5 37.2
Dysuria
Yes 54.5 0.88 (0.82, 0.94) 57.1 51.8
No 37.3 0.92 (0.90, 0.95) 35.1 39.6
Urinary frequency
Yes 61.5 0.88 (0.80, 0.96) 70.0 52.6
No 37.4 0.92 (0.90, 0.94) 34.5 40.3
Fever (>38.0°C)1
Yes 32.8 0.94 (0.90, 0.98) 28.1 37.5
No 43.9 0.91 (0.88, 0.94) 44.3 43.5
UTI-speciﬁc abdominal
pain2
Yes 54.6 0.88 (0.81, 0.93) 54.1 55.2
No 37.0 0.92 (0.90, 0.95) 35.5 38.7
Diabetes
Yes 44.1 0.94 (0.90, 0.98) 41.9 46.0
No 39.4 0.91 (0.89, 0.94) 38.4 40.5
Renal insuﬃciency
Yes 39.9 0.93 (0.89, 0.96) 37.5 42.7
No 40.7 0.92 (0.89, 0.94) 40.0 41.4
Immunosuppression
Yes 33.5 0.92 (0.88, 0.96) 33.3 33.6
No 44.2 0.91 (0.89, 0.94) 42.1 46.4
Total 40.2 — 39.1 41.8
1Two values (one of training and one of the validation set) were missing; thus, n = 611. 2This includes lower abdominal, suprapubic, and ﬂank pain.
Abbreviations: AUC: area under the receiver operating curve; CI: conﬁdence interval; SBU: signiﬁcant bacterial growth in urine culture; UFC: urine ﬂow
cytometry; UTI: urinary tract infection.
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ﬁgures are comparable to the incidence of signiﬁcant bacte-
rial growth in urine culture in other studies [23]. The rela-
tively low incidence of signiﬁcant bacterial growth in urine
cultures in immunosuppressed and febrile patients may be
explained by the relatively broad indication for obtaining a
urine culture in these patients, even when there is no great
suspicion of a urological infection.
As suggested by diﬀerent studies [20, 24, 25], one strategy
for establishing cut-oﬀ values is to maximize Youden’s index.
Our results suggest that this strategy does not lead to useful
cut-oﬀs in many clinical presentations, as the resulting
cut-oﬀs can neither be used to “rule in” (high LR(+)) nor
be used to “rule out” (LR(-)) signiﬁcant bacterial growth in
the urine culture but lead to balanced cut-oﬀs with regard
to LR(+)/LR(-). In general, cut-oﬀs established by maximiz-
ing Youden’s index should be treated cautiously, and the
detailed diagnostic performance of such tests should be dem-
onstrated. More adequate approaches to establish “optimal”
cut-oﬀs require estimating the “costs” of misdiagnoses, false
positives, and false negatives [26], a task which is hard to
accomplish. Thus, we focused on ruling out the diagnosis in
the further analyses by maximizing sensitivity. The suggested
linear discriminant analysis, LDA95 [18], is not very feasible
in everyday use, as a calculator or computer is needed to eval-
uate the results of a urine culture and the results found in this
study were not convincing. We slightly modiﬁed the formula
presented by Monsen and Ryden [18], in order to assure that
the formula was valid for all numbers of urine ﬂow bacterium
and leucocyte counts; this had no impact on the outcome.
Adapted cut-oﬀs for the clinical presentations were therefore
developed by maximizing the sensitivity of both UFC leuco-
cyte and bacterium counts and combining these into one test.
In the setting of immunosuppression, for instance, lower
cut-oﬀs for UFC bacterium and UFC leucocyte counts were
found to lead to high sensitivity (>95%). Stefanovic et al. also
studied the diagnostic performance of urine ﬂow cytometry
Table 3: Established cut-oﬀ values for UFC bacterium and leucocyte counts per μL with the highest Youden’s index and the corresponding
diagnostic performance in the validation sample in predicting signiﬁcant bacterial growth in urine culture in diﬀerent clinical scenarios.
Subgroup (no. in validation set)
Highest Youden’s
index
Diagnostic performance using the established cut-oﬀs∗
Lc (/μL) Bact (/μL) Sensitivity (%) (95% CI) Speciﬁcity (%) (95% CI) LR(+) LR(-)
Sex
Male (n = 159) 74 71 94.5 (84.9, 98.9) 71.2 (61.4, 79.6) 3.28 0.08
Female (n = 147) 169 2883 89 (79.5, 95.1) 79.7 (68.8, 88.2) 4.39 0.14
Age
>65 (n = 142) 57 63 95.5 (87.5, 99.1) 60.0 (48.0, 71.1) 2.39 0.07
≤65 (n = 164) 169 150 96.7 (88.7, 99.6) 64.1 (54.0, 73.3) 2.69 0.05
Dysuria
Yes (n = 56) 205 87 96.6 (82.2, 99.9) 66.7 (46.0, 83.5) 2.90 0.05
No (n = 250) 74 441 93.3 (87.3, 97.7) 74.8 (67.1, 81.5) 3.73 0.08
Urinary frequency
Yes (n = 38) 108 409 100 (83.2, 100) 55.6 (30.8, 78.5) 2.25 —
No (n = 268) 74 83 96.3 (90.8, 99) 60.6 (52.6, 68.2) 2.45 0.06
Fever (>38.0°C)1
Yes (n = 96) 108 527 91.7 (77.5, 98.2) 88.3 (77.4, 95.2) 7.86 0.09
No (n = 209) 171 99 94.5 (87.6, 98.2) 61.0 (51.6, 69.9) 2.42 0.09
UTI-speciﬁc abdominal pain2
Yes (n = 58) 169 128 96.9 (83.8, 99.9) 46.2 (26.6, 66.6) 1.80 0.07
No (n = 248) 69 83 95.8 (89.7, 98.9) 59.9 (51.6, 67.7) 2.40 0.07
Diabetes
Yes (n = 74) 76 1061 88.2 (72.5, 96.7) 77.5 (61.5, 89.2) 3.92 0.15
No (n = 232) 137 441 96.8 (91.0, 99.3) 77.5 (69.7, 84.2) 4.31 0.04
Renal insuﬃciency
Yes (n = 96) 74 63 95.1 (83.5, 99.4) 56.4 (42.3, 69.7) 2.18 0.08
No (n = 210) 108 470 94.3 (87.1, 98.1) 76.4 (67.9, 83.6) 4.00 0.08
Immunosuppression
Yes (n = 110) 74 127 97.3 (85.8, 99.9) 72.6 (60.9, 82.4) 3.55 0.04
No (n = 196) 151 470 94.5 (87.6, 98.2) 74.3 (64.8, 82.3) 3.68 0.07
1One patient in the validation set did not have suﬃcient data to determine if temperature > 38 0°C. 2This includes lower abdominal, suprapubic, and ﬂank pain.
Abbreviations: AUC: area under the receiver operating curve; Bact: UFC bacterium counts; CI: conﬁdence interval; Lc: UFC leucocyte counts; LR: likelihood
ratio; SBU: signiﬁcant bacterial growth in urine culture; UFC: urine ﬂow cytometry; UTI: urinary tract infection.
6 Disease Markers
in immunosuppressed patients. For high sensitivity, they
employed even lower cut-oﬀs for UFC bacterium counts ≥
20/μLor UFC leucocyte counts > 5/μL [17]. Even with this
low cut-oﬀ, the sensitivity was lower (90.6%) for immuno-
suppressed patients than for nonimmunosuppressed
patients. This is in contrast to our study, in which the higher
cut-oﬀ was suﬃcient to rule out signiﬁcant bacterial growth
in urine culture. In another study, the use of age-speciﬁc
UFC parameters was recommended [16]; it was found that
for people aged ≥65 years, a single cut-oﬀ of UFC bacterium
counts of 200/μL leads to very high sensitivity and high spec-
iﬁcity (99.1% and 91.6%, respectively) with a minimal rate of
0.87% false negative results.
Manoni et al. suggested using UFC leucocytes > 17/μL
or UFC bacteria > 125/μL to deﬁne a pathological test
[12]. Our study shows that these cut-oﬀs (Table 5, the
in-house cut-oﬀs) are valid for ruling out signiﬁcant bacte-
rial growth in urine culture in all studied clinical presenta-
tions; this cut-oﬀ is therefore recommended as a safe
rule-out cut-oﬀ in the ED. With this high-sensitivity cut-
oﬀ, as many as 30% of the urine cultures could have been
avoided in our study. Martín-Gutiérrez et al. showed that
an even higher cut-oﬀ of 200/μL for the UFC bacterium
count could help to avoid the culture of up to 60.2% of
samples in the elderly population (>65 years) [16].
However, with these cut-oﬀs, speciﬁcity was lacking, and
in some groups, such as females, people aged ≤65 years, and
dysuric patients, even higher cut-oﬀs for UFC leucocyte
counts (169/μL, 169/μL, and 205/μL, respectively) can assure
high sensitivity.
4.1. Strengths and Limitations. Our results were obtained
with the UX-2000. However, as the UX-2000 series has the
same technology as the frequently used UF-1000i series to
measure urine leucocyte and bacterium counts; our cut-oﬀs
can also be applied to the latter machines.
In contrast to many other studies that focused on UFC
cut-oﬀ values, a particular strength of this study lies in the
Table 4: Established high-sensitivity test with the use of an adapted 95 percent linear discrimination analysis equation (LDA95) and its
validation. LDA95 equation: ln UFC leucocyte + 1 > A × ln UFCbacteria + 1 + B.
Subgroup
LDA95-equat.
coeﬃcients
Diagnostic performance using the established cut-oﬀs∗
A B Sensitivity (%) (95% CI) Speciﬁcity (%) (95% CI) LR(+) LR(-)
Sex
Male (n = 159) -4.6 21.2 89.1 (77.8, 95.9) 76.0 (66.6, 83.8) 3.71 0.14
Female (n = 147) -3.4 18.9 95.9 (88.5, 99.1) 51.4 (39.4, 63.1) 1.97 0.08
Age
>65 (n = 142) -20.4 86.8 89.6 (79.7, 95.7) 70.7 (59.0, 80.6) 3.05 0.15
≤65 (n = 164) -1.6 10.5 95.1 (86.3, 99.0) 63.1 (53.0, 72.4) 2.58 0.08
Dysuria
Yes (n = 56) -1.4 10.4 96.6 (82.2, 99.9) 66.7 (46.0, 83.5) 2.90 0.05
No (n = 250) -4.5 20.8 91.9 (84.7, 96.4) 58.3 (50.0, 66.2) 2.20 0.14
Urinary frequency
Yes (n = 38) -2.3 17.8 100 (83.2, 100) 66.7 (41.0, 86.7) 3.00 —
No (n = 268) -4.2 19.7 90.7 (83.6, 95.5) 62.5 (54.5, 70.0) 2.42 0.15
Fever (>38.0°C)1
Yes (n = 96) -1.3 8.2 94.4 (81.3, 99.3) 68.3 (55.0, 79.7) 2.98 0.08
No (n = 209) -4.9 25.0 92.3 (84.8, 96.9) 66.1 (56.8, 74.6) 2.72 0.12
UTI-speciﬁc abdominal pain2
Yes (n = 58) -1.8 14.0 96.9 (83.8, 99.9) 57.7 (36.9, 76.6) 2.29 0.05
No (n = 248) -4.5 20.5 91.7 (84.2, 96.3) 63.8 (55.6, 71.4) 2.53 0.10
Diabetes
Yes (n = 74) -4.2 25.0 79.4 (62.1, 91.3) 80.0 (64.4, 90.9) 3.97 0.26
No (n = 232) -3.0 15.3 94.7 (88.0, 98.3) 61.6 (52.9, 69.7) 2.47 0.09
Renal insuﬃciency
Yes (n = 96) -2.4 13.0 87.8 (73.8, 95.9) 67.3 (54.3, 95.9) 2.68 0.18
No (n = 210) -3.9 21.0 93.1 (85.6, 97.4) 69.9 (61.0, 77.9) 3.10 0.10
Immunosuppression
Yes (n = 110) -1.0 6.5 97.3 (85.8, 99.9) 64.4 (52.3, 75.3) 2.73 0.04
No (n = 196) -5.9 31.2 91.2 (83.4, 96.1) 67.6 (57.8, 76.4) 2.82 0.13
1One patient in the validation set did not have suﬃcient data to determine if temperature > 38 0°C. 2This includes lower abdominal, suprapubic, and ﬂank pain.
Abbreviations: CI: conﬁdence interval; LDA: linear discrimination analysis; LR: likelihood ratio; UTI: urinary tract infection.
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external validity of our cohort. In their systematic review,
Shang et al. concluded that most studies were laboratory
based. Thus, it was unclear whether they were generalizable
to clinically suspected UTI [13]. On the other hand, our data
were collected in an ED population, and the results may not
be transferred to a non-ED patient population, such as a
health care center.
Furthermore, trials are recommended to evaluate the use
of clinically adapted cut-oﬀs to determine the economic
beneﬁt, as well as to quantify the impact of adapted cut-oﬀs
on the prescription of (unnecessary) antibiotics.
The greatest limitation of our study is the retrospective
design. While the quality of the extracted data can be
assured for both the exposure (UFC data) and the outcome
data (signiﬁcant bacterial growth in urine culture), as they
are hard outcomes measured in certiﬁed laboratories, the
evaluated clinical presentations were predominantly deﬁned
through the electronic medical record. Thus, information
and misclassiﬁcation bias through incomplete documenta-
tion is an important potential limitation of this study. The
number of patients in some subgroups may have been too
small to detect diﬀerences in the predictive accuracy in some
speciﬁc presentations (potentially underpowered statistics);
this is reﬂected in the wide conﬁdence intervals. Further-
more, one particularly important subgroup of patients could
not be studied with our retrospective study sample, i.e.,
patients with a high suspicion of a UTI, namely, patients
with more than one symptom, for example, dysuria, fever,
and suprapubic pain. As the sample size of this study was
small, we suggest that our results should be veriﬁed in larger,
prospective studies. As a consequence of the small sample
size, one cannot combine the results and apply them to
Table 5: Diagnostic performance of the in-house cut-oﬀs and the sensitivity-optimized cut-oﬀs for each clinical scenario.
Subgroup
Diagnostic performance using in-house cut-oﬀ
(UFC leucocyte > 17/μL, UFC bacteria > 125/μL) Optimized cut-oﬀ corresponding diagnostic performance
∗
Sensitivity (%)
(95% CI)
Speciﬁcity (%)
(95% CI)
LR(+) LR(-)
Cut-oﬀs
(/μL)
Sensitivity (%)
(95% CI)
Speciﬁcity (%)
(95% CI)
LR(+) LR(-)
Lc Bact
Sex
Male (n = 159) 96.4 (87.5, 99.6) 60.6 (50.5, 70.0) 2.44 0.06 74 17 100 (93.5, 100) 54.8 (44.7, 64.6) 2.21 —
Female (n = 147) 98.6 (92.6, 100) 37.8 (26.8, 49.9) 1.59 0.04 169 103 97.3 (90.5, 99.7) 45.9 (34.3, 57.9) 1.8 0.06
Age
>65 (n = 142) 95.5 (87.5, 99.1) 58.7 (46.7, 69.9) 2.31 0.07 57 21 100 (94.6, 100) 50.7 (38.9, 62.4) 2.03 —
≤65 (n = 164) 100 (94.1, 100.0) 45.6 (35.8, 55.7) 1.84 — 169 103 96.7 (88.7, 99.6) 60.2 (50.1, 69.7) 2.43 0.05
Dysuria
Yes (n = 56) 100 (88.1, 100) 33.3 (16.5, 54.0) 1.5 — 205 103 96.6 (82.2, 99.9) 66.7 (46.0, 83.5) 2.90 0.05
No (n = 250) 97 (91.4, 99.4) 54.3 (46, 62.4) 2.12 0.06 74 21 100 (96.3, 100) 45.7 (37.6, 54) 1.84 —
Urinary frequency
Yes (n = 38) 100 (83.2, 100) 22.2 (6.4, 47.6) 1.29 — 108 210 100 (83.2, 100) 50.0 (26.0, 74.0) 2.00 —
No (n = 268) 97.2 (92.1, 99.4) 54.4 (46.3, 62.3) 2.13 0.05 74 21 100 (96.6, 100) 47.5 (39.6, 55.5) 1.90 —
Fever (>38.0°C)1
Yes (n = 96) 97.2 (85.5, 99.9) 60.0 (46.5, 72.4) 2.43 0.05 108 14 100 (90.3, 100) 48.3 (35.2, 61.6) 1.94 —
No (n = 209) 97.8 (92.3, 99.7) 46.6 (37.4, 56.0) 1.83 0.05 171 22 96.7 (90.7, 99.3) 48.3 (39.0, 57.7) 1.87 0.07
UTI-speciﬁc abdominal
pain2
Yes (n = 58) 100 (89.1, 100) 34.6 (17.2, 55.7) 1.53 — 169 209 96.9 (83.8, 99.9) 53.8 (33.4, 73.4) 2.10 0.06
No (n = 248) 96.9 (91.1, 99.4) 53.9 (45.7, 62.1) 2.10 0.06 69 21 100 (96.2, 100) 47.4 (39.2, 55.6) 1.90 —
Diabetes
Yes (n = 74) 97.1 (84.7, 99.9) 57.5 (40.9, 73) 2.28 0.05 76 17 100 (89.7, 100) 50.0 (33.8, 66.2) 2.00 —
No (n = 232) 97.9 (92.5, 99.7) 49.3 (40.7, 57.9) 1.93 0.04 137 56 97.9 (92.5, 99.7) 55.8 (47.1, 64.2) 2.21 0.04
Renal insuﬃciency
Yes (n = 96) 95.1 (83.5, 99.4) 45.5 (32.0, 59.4) 1.74 0.11 74 21 100 (91.4, 100) 49.1 (35.4, 62.9) 2.00 —
No (n = 210) 98.9 (93.8, 100) 53.7 (44.4, 62.7) 2.13 0.02 108 54 97.7 (91.9, 99.7) 54.5 (45.2, 63.5) 2.15 0.04
Immunosuppression
Yes (n = 110) 100 (90.5, 100) 57.5 (45.4, 69.0) 2.35 — 74 24 97.3 (85.8, 99.9) 53.4 (41.4, 65.2) 2.09 0.05
No (n = 196) 96.7 (90.7, 99.3) 46.7 (36.9, 56.7) 1.81 0.07 151 21 97.8 (92.3, 99.7) 46.7 (36.9, 56.7) 1.83 0.05
1One patient in the validation set did not have suﬃcient data to determine if temperature > 38 0°C. 2This includes lower abdominal, suprapubic, and ﬂank pain.
Abbreviations: Bact: UFC bacterium counts; CI: conﬁdence interval; Lc: UFC leucocyte counts; LR: likelihood ratio; UFC: urine ﬂow cytometry; UTI: urinary
tract infection.
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patients who have a combination of the diﬀerent attributes
for which criteria were presented in this study. In general,
if more than one applicable category with adapted cut-oﬀ
exists, we recommend using the one with the lowest cut-oﬀ
for a safe exclusion of future signiﬁcant bacterial growth in
urine culture. Prospective studies are needed to address the
impact of the diagnostic accuracy for signiﬁcant bacterial
growth in urine culture for UFC parameters in the setting
in which the clinician greatly suspects a UTI. Moreover,
our design only enabled us to include people for whom a
urine culture was obtained in ordinary clinical practice. In
a prospective design, a urine culture would have been
obtained for all patients with a UFC. As the patients from
the examined presentations overlap, the results are not inde-
pendent and cannot be combined to calculate (for instance)
the positive likelihood ratio to rule out signiﬁcant bacterial
growth in urine culture in an immunosuppressed, female,
older patient.
5. Conclusions
Clinicians should be aware that in speciﬁc patient groups,
e.g., in females, the predictive accuracy of UFC leucocyte
and UFC bacterium counts to predict signiﬁcant bacterial
growth in urine culture is diminished and that the predictive
accuracy of cut-oﬀs depends on the clinical setting. On the
basis of our ﬁndings, UFC can be used to rule out signiﬁcant
bacterial growth in urine culture with high sensitivity by the
use of the cut-oﬀs for UFC bacterium counts ≤ 125/μL and
UFC leucocyte counts ≤ 17/μL—independently of the clinical
presentation, sex, age, or comorbidities such as diabetes,
renal insuﬃciency, and immunosuppression. Even higher
UFC leucocyte cut-oﬀs (169/μL, 169/μL, and 205/μL) are jus-
tiﬁed in females, people aged ≤65 years, and dysuric patients.
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